ctDNA-guided adjuvant chemotherapy for colorectal cancer-ready for prime time?
- PMID: 36055230
- DOI: 10.1016/j.ccell.2022.08.017
ctDNA-guided adjuvant chemotherapy for colorectal cancer-ready for prime time?
Abstract
In stage II colorectal cancer, adjuvant chemotherapy is controversial, and overtreatment is substantial due to suboptimal risk stratification. In a recent New England Journal of Medicine article reporting from a prospective randomized phase II trial, Tie and colleagues demonstrate how ctDNA-guided risk-stratification reduces the use of adjuvant chemotherapy without compromising recurrence risk.
Copyright © 2022. Published by Elsevier Inc.
Conflict of interest statement
Declaration of interests C.L.A. declares research funding from C2i Genomics, Delfi Diagnostics, and Natera Inc. E.H. has an unrelated sponsored research agreement with Servier and received funding from Freenome, PreAnalytiX, Illumina, and Roche and honoraria for advisory boards from Roche.
Comment on
-
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer.N Engl J Med. 2022 Jun 16;386(24):2261-2272. doi: 10.1056/NEJMoa2200075. Epub 2022 Jun 4. N Engl J Med. 2022. PMID: 35657320 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
